Table 1. Clinicopathological variables in non-obese patients (BMI <25 kg/m2) and obese patients (BMI ≥25 kg/m2) with hepatocellular carcinoma from southeast China who underwent curative resection.
| Variable | Before Propensity Matching | After Propensity Matching | ||||
|---|---|---|---|---|---|---|
| Non-obese | Obese | P | Non-obese | Obese | P | |
| (n = 242) | (n = 68) | (n = 115) | (n = 61) | |||
| BMI, kg/m2 | 21.2±2.0 | 27.0±1.8 | <0.001 | 21.2±2.6 | 26.8±1.8 | <0.001 |
| Age, yr | 49.2±11.9 | 49.8±10.4 | 0.723 | 49.6±11 | 50.3±10.6 | 0.728 |
| Male, n (%) | 210 (86.8) | 61 (89.7) | 0.520 | 102 (88.7) | 54 (88.5) | 0.973 |
| HBsAg positive, n (%) | 209 (86.4) | 54 (79.4) | 0.158 | 96 (83.5) | 50 (82.0) | 0.800 |
| HCV antibody-positive, n (%) | 10 (4.1) | 7 (10.3) | 0.095 | 7 (6.1) | 4 (6.6) | 1.000 |
| Comorbid disease, n (%) | ||||||
| Diabetes mellitus | 17 (7) | 4 (5.9) | 0.954 | 3 (2.6) | 2 (3.3) | 1.000 |
| Hypertension | 45(18.6) | 18(26.5) | 0.154 | 23(20) | 14(23) | 0.648 |
| Cardiovascular diseases | 27(11.2) | 6(8.8) | 0.581 | 17(14.8) | 6(9.8) | 0.354 |
| Respiratory diseases | 20(8.3) | 7(10.3) | 0.600 | 12(10.4) | 5(8.2) | 0.632 |
| Total bilirubin level, μmol/L | 14±6.5 | 13.9±6.5 | 0.968 | 14.4±6.7 | 14.0±6.5 | 0.671 |
| AST, median (range), U/L | 42.9 (24–53) | 47.6 (30.3–55.8) | 0.043 | 42.1 (25–49) | 44.7 (29–55) | 0.136 |
| ALT, median (range), U/L | 48.8 (29–54) | 44.4 (31–55.8) | 0.954 | 43.7 (29–50) | 44.7 (31–55.5) | 0.455 |
| Albumin, g/L | 40±4.6 | 41.3±4.6 | 0.036 | 41.5±4 | 41±4.3 | 0.446 |
| Platelet count, 109/L | 178.9±75.9 | 177.6±73.1 | 0.900 | 174.2±63.4 | 176.0±73.9 | 0.865 |
| Prothrombin time, s | 12.9±1.6 | 12.9±1.9 | 0.765 | 12.9±1.5 | 12.9±1.9 | 0.999 |
| AFP ≥400 ng/mL, n (%) | 70 (28.9) | 17 (25.0) | 0.524 | 30 (26.1) | 14 (23.0) | 0.647 |
| Solitary tumor, n (%) | 165 (68.2) | 58 (85.3) | 0.006 | 93 (80.9) | 51 (83.6) | 0.654 |
| Tumor size, median (range), cm | 6 (3.5–8) | 5.3 (3.6–6.6) | 0.154 | 5.6 (3.5–7.5) | 5.2 (3.5–6.6) | 0.647 |
| Tumor capsule, n (%) | 135 (55.8) | 42 (61.8) | 0.379 | 49 (42.6) | 23 (37.7) | 0.529 |
| Liver cirrhosis, n (%) | 188 (77.7) | 57(83.8) | 0.272 | 95 (82.6) | 51 (83.6) | 0.867 |
| BCLC stage A/B, n (%) | 194 (80.2)/48 (19.8) | 60(88.2)/8(11.8) | 0.126 | 97 (84.3)/18 (15.7) | 53 (86.9)/8 (13.1) | 0.652 |
| Minor/major resection, n (%) | 105 (43.4)/137 (56.6) | 31(45.6)/37(54.4) | 0.747 | 56 (48.7) /59 (51.3) | 34(55.7)/27(44.3) | 0.374 |
Data are mean ± standard deviation or medium (25th-75th interquartile range) unless otherwise indicated
Abbreviations: AFP, alpha-fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BCLC, Barcelona Clinic Liver Cancer.